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present study was a farmer or hunter, but most
owned, or formerly kept, dogs or cats, and these
could be a possible risk-factor for this infection
[15,16]. Overall, the results of this study suggest
that clinicians and health authorities in Slo-
venia should give greater attention to AE in the
future.
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ABSTRACT
Paediatric patients hospitalised with varicella
(n = 1575) were reported to a French national
network between March 2003 and July 2005.
Superinfection was identified in 50.3% of cases,
principally of skin and soft-tissue (36.5%). The risk
of superinfection increased with fever relapse, use
of non-steroidal anti-inflammatory drugs, pro-
longed fever, an age of 1–5 years, and contamina-
tion at the childminder’s home. Neurological com-
plications were observed in 7.8% of cases, while
pulmonary complications were less frequent
(3.1%). Forty-nine patients had sequelae and eight
patients died. Surveillance should continue in
France with a view to the future implementation
of a universal vaccination programme.
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Varicella is a mild infectious disease preventable by
vaccination [1,2]. Only high-risk individuals are
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currently targeted for varicella vaccination in
France, and 700 000 cases of varicella are diagnosed
annually (estimated incidence 1420 ⁄ 100 000),
with 90% occurring in children aged <10 years
[3] (http://rhone.b3e.jussieu.fr/senti/docs/bilans/
2004/BilanRS_2004–050314V15.pdf 2004). Compli-
cations are reported in 8–9% of cases, with 15–25
deaths each year, mainly in adults and the elderly
[4,5]. In total, 3500 patients are hospitalised each
year with a diagnosis of varicella (with 75% aged
<15 years), but only 33% are recorded as having
complications [4]. However, complications are the
primary cause of varicella-related hospitalisations
according to regional French paediatric studies
[6,7]. In order to better estimate the burden of
paediatric hospitalisations caused by varicella in
France, a national surveillance network was estab-
lished. The present report presents a descriptive
analysis of the results of surveillance for the first
2 years.
In total, 200 paediatric wards in hospitals located
throughout France participated in the study. Each
patient admitted for ongoing varicella and ⁄ or
complications or events attributed to varicella
was recorded. Hospitalisations unrelated to vari-
cella, and conditions with an onset of varicella
>5 days after admission, were excluded. For each
case, a standard form recording age, gender,
underlying conditions, reason for admission,
source of infection, nature and type of any varicel-
la-associated complications, and outcome was
completed by a designated clinical investigator.
Data were analysed using Statview II (Abacus
Concepts, Cary, NC, USA) and Stata 8 (StataCorp,
College Station, TX, USA) software to compare
frequencies, perform chi-square tests and conduct
bivariate and multivariate analyses. The contri-
bution of selected factors, e.g., age, gender, source
of varicella-zoster virus infection, use of non-
steroidal anti-inflammatory drugs, corticosteroid
therapy, immunodeficiency, and severity of
varicella infection (extensive and ⁄ or haemorrhag-
ic), as factors potentially related to superinfection,
was analysed by logistic regression models.
Overall, 165 paediatric wards contributed at
least one case report form between March 2003
and July 2005, describing a total of 1575 cases,
including 38 (2.4%) that required intensive care.
The median age of the patients was 2.0 years;
87.5% were aged <5 years, and 2.7% were
neonates. The male:female ratio was 1:1.25. The
majority (73.7%) of cases occurred in the spring
and early summer months, with a peak in June
(18.8%) and a nadir in September (1.0%). The
mean length of hospitalisation was 5 (median
4.0 ± 3.7) days. The source of varicella-zoster
virus infection was identified for 56.1% of cases,
of which the patient’s household accounted for
64%, a day care centre ⁄ school for 27.5%, and a
childminder’s home for 4.9%.
In 41.8% of cases, the following risk-factors for
severe or complicated varicella were identified:
corticosteroid therapy (106 cases, 8.3%); systemic
therapy (40 cases, 3.1%); topical therapy (39 cases,
3.1%); and inhaled therapy (39 cases, 3.1%).
Forty-two (2.7%) children were aged <1 month,
20 (1.3%) had received immunosuppressant
chemotherapy, and four (0.3%) were infected
Table 1. Complications and other potential reasons for
hospitalisation with varicella infection
Identified complication n (%)b
Superinfectionsa 792 (50.3)
Skin ⁄ soft-tissue infection 575 (36.5)
Cellulitis 390 (24.8)
Abscess 114 (7.2)
Necrotising skin lesion 73 (4.6)
Scalded skin syndrome 44 (2.8)
Necrotising fasciitis 13 (0.8)
Other localisations 198 (12.6)
Bacterial pneumonia 49 (3.1)
Ear, nose and throat 45 (2.9)
Bacteraemia 34 (2.2)
Lower respiratory tract infections 28 (1.8)
Arthritis 22 (1.4)
Shock 11 (0.7)
Pleurisy 10 (0.6)
Other infections 10 (0.6)
Osteomyelitis 9 (0.6)
Bacterial meningitis 3 (0.2)
Neurological complications 127 (8.1)
Cerebellitis 83 (5.3)
Encephalitis 25 (1.6)
Other neurological complications 15 (1.0)
Aseptic meningitis 11 (0.7)
Neuritis 6 (0.4)
Cerebral vascular thrombosis 1 (0.06)
Pulmonary complications 49 (3.1)
Varicella pneumonia 38 (2.4)
Acute respiratory distress syndrome 11 (0.7)
Haematological complications 30 (1.9)
Thrombocytopenic purpura 19 (1.2)
Other haematological complications 5 (0.3)
Disseminated intravascular coagulopathy 4 (0.3)
Haemorrhagic syndrome 3 (0.2)
Other complications 141 (9.0)
Febrile seizure 116 (7.4)
Hepatitis 19 (1.2)
Arthritis 5 (0.3)
Inappropriate anti-diuretic hormone syndrome 3 (0.2)
Other reasons for hospitalisation
Fever 1042 (66.2)
Risk-factor or underlying condition 659 (41.8)
Severity of infection 344 (21.8)
Digestive problems 200 (12.7)
Social considerations 73 (4.6)
Intercurrent disease 59 (3.7)
aPresumed or confirmed.
bReasons for hospitalisation are not exclusive and percentages do not add up to
100%.
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with human immunodeficiency virus. Other con-
ditions, i.e., atopic dermatitis (with or without
local steroid treatment), underlying disease and
recent non-steroidal anti-inflammatory drug use
(ibuprofen and ⁄ or acetylsalicylic acid), were
associated with 10%, 4.1% and 18% of cases,
respectively.
The main reason for hospitalisation was the
occurrence of a complication (76.2%; Table 1).
Bacterial superinfections were the most fre-
quent type of complication (792 cases, 50.3%),
mainly involving skin and soft-tissue (36.5%);
these were more prevalent (82.1%) in children
aged <5 years (mean age 2.1 ± 1.7 years, median
age 2.0 years). Using a multiple regression analy-
sis model, the risk of superinfection increased
with fever relapse (OR 3.06, 95% CI 1.5–6.4), non-
steroidal anti-inflammatory drug use (OR 2.65,
95% CI 1.8–3.4), prolonged fever (OR 2.25, 95%
CI 1.5–3.3), an age of 1–5 years (OR 2.25, 95%
CI 1.4–3.8), contamination at the childminder’s
home (OR 2.13, 95% CI 1.0–4.4) and an age of
<1 year (OR 1.72, 95% CI 1.0–2.9). A bacterial
agent was identified in 299 (37.8%) superinfec-
tions (Table 2). The two pathogens isolated most
frequently were Staphylococcus aureus (n = 176)
and group A b-haemolytic streptococci (n = 113).
Both of these pathogens could be invasive,
and they were isolated from blood in 24 cases
each. Other pathogens, e.g., Streptococcus pneumo-
niae (n = 11), were identified mainly in respirat-
ory superinfections. Neisseria meningitidis was
identified in three cases of bacterial meningitis.
Neurological complications (excluding febrile
seizure) occurred more frequently in older chil-
dren (mean age 4.0 ± 3 years, median 3.0 years),
and represented the most frequent complication
(19.6%) in individuals aged >6 years.
The outcome was favourable in most cases,
with sequelae recorded for only 49 patients; these
sequelae were mostly cutaneous (44 scars) and
neurological (n = 5), but eight patients died. All
but one (nephrotic syndrome) of the eight patients
who died were considered to be immunocompe-
tent before admission. Most died during a fever or
a sudden shock event shortly after admission,
suggesting a septic or toxic mechanism.
This study is one of the largest studies of
varicella-associated hospitalisations, and is the
largest study carried out in Europe to date.
Hospitalisation for varicella and varicella-associ-
ated complications was justified by valid medical
reasons in most cases. In the present study,
varicella-associated complications were frequent,
with most occurring in children without any
identified risk-factors. Most complications were
superinfections, with a predominance of skin and
soft-tissue localisations. As reported previously,
Staph. aureus and group A b-haemolytic strepto-
cocci are the predominant agents responsible for
Table 2. Pathogenic agents and infectious complications associated with varicella infection
No. of cases Staphylococcus aureus GABHS GABHS + Staph. aureus Other
Total
Pathogen
identified
No. of
infectionsa
No. of invasive
infectionsa
No. of
infections
No.of invasive
infectionsa
No. of
infections
No. of invasive
infectionsa
No. of
infections
No. of invasive
infectionsa
Cellulitis 390 161 91 6(bl) 54 5(bl) 11 1(bl) 2 Staph. epid.
1 Hi
1 Sp + Hi
1 SA + Hi + MC
0
0
0
Abscess 114 44 19 1(af) 23 3(bl) + 1(af) 1 0 1 SA + Hi + MC 0
Necrotising
skin lesion
73 27 22 3(bl) 3 2(bl) + 1(pl) 1 0 1 Strep. fugines 0
Scalded skin
syndrome
44 26 23 0 1 0 1 1(bl) 1 Staph. epid. 0
Necrotising
fasciitis
13 10 3 0 7 1(bl) 0 0
Arthritis 22 14 5 2(bl) + 1(af) 8 3(bl) + 3(af) 0 1 Kingella 1(af)
Osteomyelitis 9 7 3 1(af) 2 1(bl) + 1(af) 0 1 Sp 0
Pneumonia and ⁄ or
pleurisy
50 11 1 1(bl) 5 3(pl) + 1(af) 0 5 Sp 1(bl) + 1(pl)
Shock 11 8 3 3(bl) 3 1(af) 0 1 Staph. epid.
1 Sp
0
1(pl)
Bacteraemia 34 31 11 9(bl) 12 9(bl) + 1(pl) 3 3(bl) 2 Staph. epid.
1 E. coli
2 Sp
1(bl)
0
1(bl) + 1(pl)
aSite of invasive infection: af, articular fluid; bl, blood; pl, pleura.
Staph. epid., Staphylococcus epidermidis; SA, Staphylococcus aureus; GABHS, group A b-haemolytic streptococci; Hi, Haemophilus influenzae; Sp, Streptococcus pneumoniae; MC,
Moraxella catarrhalis.
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superinfection associated with varicella in chil-
dren, and both pathogens can be invasive [8,9]. A
recent increase in the frequency of invasive group
A b-haemolytic streptococcal infection in children
has been reported in France, but the absence
of previous data concerning varicella prevents
comparison with increases reported previ-
ously in the USA [9–11] (http://www.invs.sante.
fr/publications/2005/snmi/pdf/bacteriemies_
meningites.pdf). Strep. pneumoniae was isolated
mostly from patients with respiratory symptoms,
which is consistent with the known epidemiology
of pneumococcal infections among young chil-
dren in France before the implementation of
universal vaccination [12]. More surprising was
the fact that N. meningitidis was the only pathogen
identified in three patients with bacterial menin-
gitis [13,14]. Case reports of a chronological
relationship between invasive meningococcal
disease and varicella have been published
previously. Co-infection with varicella is poss-
ible, although initial varicella infection might
have resulted in local mucosal lesions and
immunosuppression, and thereby lowered
the mucosal threshold for invasive bacterial
superinfection.
Paediatric varicella represents an avoidable
burden of hospitalisation and complications in
France. Surveillance of varicella-associated com-
plications is of interest and should be used to
monitor the impact of varicella immunisation
policies.
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